Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 19/20 | 0.97 |
| ▸ | PDGFRA | P16234 | 19/20 | 0.97 |
| ▸ | EGFR | P00533 | 1/20 | 0.97 |
| ▸ | INSR | P06213 | 1/20 | 0.97 |
| ▸ | LCK | P06239 | 1/20 | 0.97 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842647 | 0.99 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL842648 | 0.99 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL3393843 | 0.99 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL6896444 | 0.97 | PDGFRB (0.97) | PDGFRBPDGFRAEGFRINSRLCK | |
| Hydrochloric Acid SCHEMBL1401374 | 0.97 | PDGFRB (0.97) | PDGFRBPDGFRAEGFRINSRLCK | |
| Hydrochloric Acid SCHEMBL7872629 | 0.97 | PDGFRB (0.97) | PDGFRBPDGFRAEGFRINSRLCK | |
| Sulfuric Acid SCHEMBL3047526 | 0.93 | PDGFRB (0.88) | PDGFRBPDGFRAEGFRINSRLCK | |
| Sulfuric Acid SCHEMBL2788130 | 0.93 | PDGFRB (0.88) | PDGFRBPDGFRAEGFRINSRLCK | |
| Sulfuric Acid SCHEMBL3886006 | 0.93 | PDGFRB (0.88) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL8133287 | 0.93 | PDGFRB (0.88) | PDGFRBPDGFRAEGFRINSRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696434-B2 | CONTROLLING CELL DIFFERENTIATION, CELL PROLIFERATION | AVENTIS PHARMACEUTICALS INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030130285-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130285-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, PTK6 | PDGFRB 27/4885PDGFRA 32/4885EGFR 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.